StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Treasury Action More than a Wrinkle for Pfizer (PFE)/Allergan (AGN) Deal - Jefferies
April 5, 2016 7:19 AM
Jefferies analyst Jeffrey Holford said the new Treasury action looks like more than just a wrinkle for the Pfizer (NYSE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Mergers and Acquisitions
Next Articles
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM
Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
April 6, 2016 7:13 AM
Allergen's (AGN) Stand-Alone Price Target is $282 at Deutsche Bank
April 5, 2016 3:45 PM
Buy Allergen (AGN) at $220 Regardless of Deal Outcome - Leerink
April 5, 2016 8:54 AM
New Treasury Action Could Block, or Significantly Change Pfizer (PFE)/Allergan (AGN) Deal - BMO Capital
April 5, 2016 6:53 AM
Allergen (AGN) Trading Below Standalone Value Following New Treasury Action - RBC
April 5, 2016 6:42 AM
Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential Impact
April 5, 2016 6:37 AM
Pfizer (PFE) Conducting Review of U.S. Treasury Notice, Won't Speculate on Potential Effect - Bloomberg, Citing Spokeswoman
April 4, 2016 5:53 PM
Allergan (AGN) Slammed on New U.S. Treasury Inversion Action; Pfizer (PFE) Higher
April 4, 2016 5:24 PM
